The new clearance specifies that Zoloft may be marketed for the treatment of panic disorder, with or without agoraphobia, an incapacitating anxiety that can restrict people to their homes. In clinical trials with adult patients, Zoloft demonstrated significant reduction in frequency of panic attacks without regard to age, gender or race. Patients suffering from panic disorder experience recurrent, unexpected panic attacks. Some of the more common symptoms include heart palpitations, sensations of shortness of breath, dizziness and fear of losing control or going crazy. Usually, however, these side effects do not result in discontinuation of treatment.
Panic disorder is two to three times more prevalent among women.
Although the age at which this disorder develops can vary, typically, its onset occurs between late adolescence and the mid-30s. Pfizer Inc is a research-based health care company with global operations.